These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 21357709)

  • 1. Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy.
    Eskazan AE; Soysal T; Ongoren S; Gulturk E; Ferhanoglu B; Aydin Y
    Haematologica; 2011 Mar; 96(3):e15; author reply e16-7. PubMed ID: 21357709
    [No Abstract]   [Full Text] [Related]  

  • 2. Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development.
    Breccia M; Alimena G
    Expert Opin Drug Saf; 2010 Sep; 9(5):713-21. PubMed ID: 20722490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily.
    Krauth MT; Herndlhofer S; Schmook MT; Mitterbauer-Hohendanner G; Schlögl E; Valent P
    Haematologica; 2011 Jan; 96(1):163-6. PubMed ID: 20934998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia.
    Latagliata R; Breccia M; Fava C; Stagno F; Tiribelli M; Luciano L; Gozzini A; Gugliotta G; Annunziata M; Cavazzini F; Ferrero D; Musto P; Capodanno I; Iurlo A; Visani G; Crugnola M; Calistri E; Castagnetti F; Vigneri P; Alimena G
    Hematol Oncol; 2013 Jun; 31(2):103-9. PubMed ID: 22815278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pleural effusions due to dasatinib.
    Brixey AG; Light RW
    Curr Opin Pulm Med; 2010 Jul; 16(4):351-6. PubMed ID: 20375898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term pattern of pleural effusion from chronic myeloid leukemia patients in second-line dasatinib therapy.
    Kim D; Goh HG; Kim SH; Cho BS; Kim DW
    Int J Hematol; 2011 Oct; 94(4):361-371. PubMed ID: 21901399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combination of thymosin and methylprednisolone for the treatment of a patient with colonic ulcers, subcutaneous nodules, and pleural effusion after dasatinib treatment for chronic myeloid leukemia.
    Chen J; Zheng Z; Shen J; Zhou Y
    Leuk Lymphoma; 2010 May; 51(5):941-3. PubMed ID: 20350280
    [No Abstract]   [Full Text] [Related]  

  • 8. Dasatinib-induced pleural effusions: a lymphatic network disorder?
    Goldblatt M; Huggins JT; Doelken P; Gurung P; Sahn SA
    Am J Med Sci; 2009 Nov; 338(5):414-7. PubMed ID: 19838099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib.
    Masiello D; Gorospe G; Yang AS
    J Hematol Oncol; 2009 Nov; 2():46. PubMed ID: 19909541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The incidence of pleural and pericardial effusion is not higher in patients receiving dasatinib at low doses. (Reply).
    Visani G; Breccia M; Montefusco E; Morra E; Santini V; Isidori A
    Haematologica; 2011 Apr; 96(4):e23-4; author reply e25. PubMed ID: 21454871
    [No Abstract]   [Full Text] [Related]  

  • 11. Safe switching from dasatinib to nilotinib after a 1-month off-drug period for persistent pleural effusion in patients with chronic myelogenous leukemia in chronic phase.
    Nagata Y; Fukuda S; Kobayashi T; Yamashita T; Ohashi K; Sakamaki H; Akiyama H
    Int J Hematol; 2010 Apr; 91(3):539-41. PubMed ID: 20191333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dasatinib, a multikinase inhibitor: therapy, safety, and appropriate management of adverse events.
    Shayani S
    Ther Drug Monit; 2010 Dec; 32(6):680-7. PubMed ID: 20864900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe dyspnoea in a patient with chronic myelogenous leukaemia on a tyrosine kinase inhibitor.
    Ustun C; Randall N; Podgaetz E; Amin K; Dincer HE
    Thorax; 2015 Jul; 70(7):701-4. PubMed ID: 25935168
    [No Abstract]   [Full Text] [Related]  

  • 14. Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors.
    Kelly K; Swords R; Mahalingam D; Padmanabhan S; Giles FJ
    Target Oncol; 2009 Apr; 4(2):99-105. PubMed ID: 19381453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib.
    Breccia M; Latagliata R; Stagno F; Luciano L; Gozzini A; Castagnetti F; Fava C; Cavazzini F; Annunziata M; Russo Rossi A; Pregno P; Abruzzese E; Vigneri P; Rege-Cambrin G; Sica S; Pane F; Santini V; Specchia G; Rosti G; Alimena G
    Haematologica; 2011 Oct; 96(10):1457-61. PubMed ID: 21685471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.
    Quintás-Cardama A; Kantarjian H; O'brien S; Borthakur G; Bruzzi J; Munden R; Cortes J
    J Clin Oncol; 2007 Sep; 25(25):3908-14. PubMed ID: 17761974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series.
    Bergeron A; Réa D; Levy V; Picard C; Meignin V; Tamburini J; Bruzzoni-Giovanelli H; Calvo F; Tazi A; Rousselot P
    Am J Respir Crit Care Med; 2007 Oct; 176(8):814-8. PubMed ID: 17600277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dasatinib in chronic myelogenous leukemia.
    Kathula SK
    N Engl J Med; 2006 Sep; 355(10):1062; author reply 1063-4. PubMed ID: 16957155
    [No Abstract]   [Full Text] [Related]  

  • 19. Dasatinib, large granular lymphocytosis, and pleural effusion: useful or adverse effect?
    Paydas S
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):242-7. PubMed ID: 24210599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
    Zwaan CM; Rizzari C; Mechinaud F; Lancaster DL; Lehrnbecher T; van der Velden VH; Beverloo BB; den Boer ML; Pieters R; Reinhardt D; Dworzak M; Rosenberg J; Manos G; Agrawal S; Strauss L; Baruchel A; Kearns PR
    J Clin Oncol; 2013 Jul; 31(19):2460-8. PubMed ID: 23715577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.